Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly ...

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Earnings Report 5.302 USD Q4 2024 Earnings Release 02/06/2025 Earnings Report 4.954 USD Q1 2025 Earnings Release 05/01/2025 Earnings Report 5.770 USD Q2 2025 Earnings Release 08/07/2025 Earnings ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare ... For Mounjaro, the diabetes treatment, Q4 sales will total $3.5 billion -- well short of analyst estimates of $4.4 billion.

Novo Nordisk A/S, GE HealthCare Technologies Inc. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...